---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-057140"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:50:29.557017+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Quoin Q1 net loss $5M; FDA says single Phase 3 may suffice for QRX003

## Summary
- Net loss $5.0M in Q1 2026 vs $3.8M in Q1 2025; cash $14M expected to fund operations into 2027.
- FDA granted Fast Track Designation for QRX003 (Netherton Syndrome); Type C meeting indicated single Phase 3 may support U.S. approval.
- Phase 3 patient recruitment on track to complete by end of 2026; potential NDA filing in 2027.
- Japan MHLW confirmed QRX003 qualifies for Orphan Drug and Fast Track review; Saudi FDA Breakthrough Medicine Designation application filed.
- QRX009 topical rapamycin platform advancing; planned IND submission for additional indication by Q3 2026.

## SEC filing metadata
- accession: 0001104659-26-057140
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465926057140/0001104659-26-057140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465926057140/tm2613938d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-057140
- JSON: https://secwatch.observer/filing/0001104659-26-057140.json
- Plain text: https://secwatch.observer/filing/0001104659-26-057140.txt

## Source-grounded claims
- claim_id: 63d1d35bcb6b9d1f0ca1a5863287f8253a225694
  claim: Quoin Pharmaceuticals, Ltd. reported preliminary financial results for first quarter 2026.
  evidence_excerpt: On May 7, 2026 Quoin Pharmaceuticals Ltd. (the “Company”) announced its first quarter 2026 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465926057140/0001104659-26-057140-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.